Download PDF
Thromb Haemost 1971; 26(02): 311-314
DOI: 10.1055/s-0038-1653678
Originalarbeiten – Original Articles – Travaux Originaux
Schattauer GmbH

An Accelerated Red-Cell Hemagglutination Inhibition Immunoassay for Measuring Fibrinogen Degradation Products in Human Serum

R Fischer
1   Central Hematology Laboratory, Inselspital, and University of Berne, School of Medicine, Berne, Switzerland
,
M Furlan
1   Central Hematology Laboratory, Inselspital, and University of Berne, School of Medicine, Berne, Switzerland
,
E. A Beck   *
1   Central Hematology Laboratory, Inselspital, and University of Berne, School of Medicine, Berne, Switzerland
› Author AffiliationsThis work was supported in part by research grant 3.102.69 from the Swiss National Foundation. The skillful technical assistance of Miss C. Lynch is gratefully acknowledged
Further Information

Publication History

Publication Date:
24 July 2018 (online)

Also available at
    Permissions and Reprints

Summary

A further modification of Merskey’s hemagglutination inhibition assay for measurement of fibrinogen degradation products (FDP) in human serum was developed. Blood is clotted in the presence of protamine chloride (25 u/ml), in addition to thrombin and s-aminocaproic acid, and at room temperature. Defibrination is complete within 5 min even in blood obtained from patients on heparin treatment. The hemagglutination immunoassay was also considerably accelerated by immediate addition of sensitized red cells to the mixtures of antiserum and antigen dilutions at 37° C. Accurate readings of FDP titers may thus be obtained within 20 min following venipuncture.

* Address requests for reprints to: Prof. E. A. Beck, Hamatologisches Zentrallabor, Inselspital, CH-3008 Bern, Switzerland.


 

  • References

  • 1 Derechin M. Caractères généraux de la paracoagulation fibrinoly tique. Rev. Hémat 10: 35 1955;
    PubMedSearch in Google Scholar
  • 2 Marder V. J, Shulman N. R. High molecular weight derivatives of human fibrinogen produced by plasmin. II. Mechanism of their anticoagulant activity. J. Biol. Chem 244: 2120 1969;
    PubMedSearch in Google Scholar
  • 3 Marder V. J, Shulman N. R, Carroll W. R. High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physicochemical and immunochemical characterization. J. Biol. Chem 244: 2111 1969;
    PubMedSearch in Google Scholar
  • 4 Merskey C, Kleiner G. J, Johnson A. J. Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment. Blood 28: 1 1966;
    PubMedSearch in Google Scholar
  • 5 Merskey G, Lalezari P, Johnson A. J. A rapid, simple, sensitive method for measuring fibrinolytic split products in human serum. Proc. Soc. exp. Biol. (N. Y) 131: 871 1969;
    CrossrefPubMedSearch in Google Scholar
  • 6 Thomas D. P, Niewiarowski S, Myers A. R, Bloch K. J, Colman R. W. A comparative study of four methods for detecting fibrinogen degradation products in patients with various diseases. New Engl. J. Med 283: 663 1970;
    CrossrefPubMedSearch in Google Scholar
  • 7 Triantaphyllopoulos D. C. Anticoagulant effect of incubated fibrinogen. Canad. J. Biochem 36: 250 1958;
    PubMedSearch in Google Scholar